Σκοπός του Ιntelligence-pharma είναι να σας ενημερώνει για τις τελευταίες τάσεις και αναλύσεις σχετικά με τον ταχέως μεταβαλλόμενο κόσμο του φαρμάκου.
What Did Ian Read Learn From Trump? Pfizer Inc. CEO Ian Read may have as much insight as anyone in the pharma world into US President Donald Trump’s thinking on drug … Continue Reading Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk
Takeda Pharmaceutical‘s Alunbrig (brigatinib) hit its Phase III primary endpoints of statistically significant improvement in progression-free survival compared to crizotinib (Pfizer’s Xalkori) in a subset of lung cancer patients following the first pre-specified … Continue Reading Takeda’s Alunbrig Shows Superiority Over Pfizer’s Xalkori in Some Lung Cancer Patients
Glancing at the headlines, it might seem like drug companies have a hard time avoiding anger over the prices of medications. But public opinions about them have changed in … Continue Reading RANKED: These are the most and least reputable drug companies in the world
Drug companies have been hit hard this year. Public opinion, trust and reputation of pharmaceutical companies appear to be eroding, according to a new analysis from the research consulting … Continue Reading These are the most — and least — reputable drug companies in the US
Seattle-based Presage Biosciences made several key moves today that include a $6 million investment from pharma giants Takeda and Celgene and also tapped a new chief executive officer. Presage said the investment from Takeda and Celgene will … Continue Reading Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
H εξαγορά της βρετανικής φαρμακοβιομηχανίας Shire από τον ιαπωνικό κολοσσό Takeda Pharmaceutical Limited αντί του ποσού των 62 δισ. δολ φαίνεται τουλάχιστον μέχρι στιγμής να είναι το μεγαλύτερο deal της … Continue Reading Το τοπίο εξαγορών και επενδύσεων στις φαρμακευτικές τον Μάιο
Looking ahead to 2018, the most promising products in pharma’s pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with … Continue Reading The 2018 pipeline report: Aspiring assets to keep an eye on
Η ιαπωνική φαρμακευτική Takeda κατέληξε σε προκαταρκτική συμφωνία για την εξαγορά της Shire, προσφέροντάς της 64 δισ. δολάρια σε ρευστό και μετοχές. Ετσι, η Takeda εξασφαλίζει μία θέση μεταξύ των … Continue Reading Εξαγορά της ιρλανδικής Shire από την Takeda αντί 64 δισ. δολ.
